

Luigi Pasini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3239435/publications.pdf>

Version: 2024-02-01

18
papers

363
citations

1039880

9
h-index

887953

17
g-index

18
all docs

18
docs citations

18
times ranked

985
citing authors

#	ARTICLE	IF	CITATIONS
1	Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative <i>EGFR</i> profiling in vesicular RNA. <i>Molecular Oncology</i> , 2021, 15, 2423-2438.	2.1	10
2	Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 809-817.	1.1	2
3	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences. <i>Frontiers in Pharmacology</i> , 2021, 12, 745701.	1.6	1
4	Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy. <i>Cancers</i> , 2020, 12, 40.	1.7	20
5	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3532.	1.8	5
6	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998.	1.0	28
7	Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 131.	1.0	42
8	Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. <i>EBioMedicine</i> , 2019, 43, 114-126.	2.7	40
9	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S265-S279.	1.3	17
10	Molecular Pathways in Melanomagenesis. , 2019, , 623-642.		0
11	A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1405-1415.	1.9	25
12	TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines. <i>BMC Cancer</i> , 2015, 15, 777.	1.1	23
13	AURA 2. <i>Translation</i> , 2014, 2, e27738.	2.9	71
14	Increased frequency of minimal homozygous deletions is associated with poor prognosis in primary malignant melanoma patients. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 487-496.	1.5	7
15	Genome-wide profiling of copy number alterations in cancer: focus on melanoma. <i>Biomedical Reviews</i> , 2014, 24, 11.	0.6	1
16	SHC4 (SHC (Src homology 2 domain containing) family, member 4). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	1
17	Melanoma: targeting signaling pathways and RALP. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 93-104.	1.5	8
18	Regulation of SRC-3 Intercompartmental Dynamics by Estrogen Receptor and Phosphorylation. <i>Molecular and Cellular Biology</i> , 2007, 27, 6913-6932.	1.1	62